Have your own idea? Try our Stock Screener
Taiwanese (TAIEX) Clinical Research and Equipment Industry Analysis
UpdatedApr 26, 2026
DataAggregated Company Financials
Companies11
- 7D1.8%
- 3M2.1%
- 1Y6.2%
- YTDn/a
In the last week, the Clinical Research and Equipment industry is up 1.8%, with Locus Cell up 19%. Meanwhile, EirGenix actually underperformed within the industry, shrinking 9.9% in the last week. In the last 12 months, the industry was up 6.2%.
Industry Valuation and Performance
Has the Taiwanese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 26 Apr 2026 | NT$35.3b | NT$2.5b | -NT$767,980,000.00 | 21.9x | -46x | 14.1x |
| Tue, 24 Mar 2026 | NT$31.2b | NT$2.5b | -NT$747,966,000.00 | 20.7x | -41.7x | 12.4x |
| Thu, 19 Feb 2026 | NT$33.3b | NT$2.4b | -NT$689,929,000.00 | 23.8x | -48.3x | 13.7x |
| Sat, 17 Jan 2026 | NT$35.0b | NT$2.4b | -NT$689,929,000.00 | 25.4x | -50.7x | 14.4x |
| Mon, 15 Dec 2025 | NT$35.6b | NT$2.4b | -NT$670,921,000.00 | 21.3x | -53x | 14.5x |
| Wed, 12 Nov 2025 | NT$35.3b | NT$2.5b | -NT$870,437,000.00 | 17.2x | -40.5x | 14.4x |
| Fri, 10 Oct 2025 | NT$38.0b | NT$2.5b | -NT$870,437,000.00 | 19x | -43.6x | 15.5x |
| Sun, 07 Sep 2025 | NT$35.9b | NT$2.5b | -NT$819,216,000.00 | 20.4x | -43.8x | 14.6x |
| Tue, 05 Aug 2025 | NT$33.5b | NT$2.5b | -NT$600,003,000.00 | 21.2x | -55.8x | 13.6x |
| Thu, 03 Jul 2025 | NT$33.9b | NT$2.5b | -NT$600,003,000.00 | 22.9x | -56.6x | 13.8x |
| Sat, 31 May 2025 | NT$33.7b | NT$2.5b | -NT$600,003,000.00 | 22.7x | -56.2x | 13.7x |
| Mon, 28 Apr 2025 | NT$31.1b | NT$2.5b | -NT$540,128,000.00 | 23.7x | -57.6x | 12.6x |
| Wed, 26 Mar 2025 | NT$36.6b | NT$2.4b | -NT$560,979,000.00 | 29.5x | -65.2x | 15.2x |
| Fri, 21 Feb 2025 | NT$37.3b | NT$2.6b | -NT$854,432,000.00 | 24x | -43.7x | 14.6x |
| Sun, 19 Jan 2025 | NT$37.1b | NT$2.6b | -NT$854,432,000.00 | 23.2x | -43.4x | 14.5x |
| Tue, 17 Dec 2024 | NT$33.9b | NT$2.6b | -NT$854,432,000.00 | 24.7x | -39.7x | 13.2x |
| Thu, 14 Nov 2024 | NT$41.2b | NT$2.5b | -NT$712,402,000.00 | 24.3x | -57.8x | 16.4x |
| Sat, 12 Oct 2024 | NT$40.7b | NT$2.3b | -NT$836,610,000.00 | 22.1x | -48.7x | 17.9x |
| Mon, 09 Sep 2024 | NT$40.3b | NT$2.3b | -NT$836,610,000.00 | 22.5x | -48.1x | 17.7x |
| Wed, 07 Aug 2024 | NT$37.9b | NT$2.1b | -NT$797,765,000.00 | 29.5x | -47.5x | 17.8x |
| Fri, 05 Jul 2024 | NT$45.0b | NT$2.1b | -NT$797,765,000.00 | 34.3x | -56.4x | 21.1x |
| Sun, 02 Jun 2024 | NT$41.0b | NT$2.1b | -NT$797,765,000.00 | 32.4x | -51.4x | 19.2x |
| Tue, 30 Apr 2024 | NT$40.1b | NT$2.1b | -NT$914,899,000.00 | 32.4x | -43.9x | 18.9x |
| Thu, 28 Mar 2024 | NT$40.5b | NT$2.1b | -NT$903,875,000.00 | 31.4x | -44.9x | 19.2x |
| Sat, 24 Feb 2024 | NT$43.6b | NT$2.1b | -NT$610,218,000.00 | 33x | -71.5x | 21x |
| Mon, 22 Jan 2024 | NT$44.2b | NT$2.1b | -NT$610,218,000.00 | 32.9x | -72.5x | 21.3x |
| Wed, 20 Dec 2023 | NT$48.0b | NT$2.1b | -NT$610,218,000.00 | 33.9x | -78.7x | 23.2x |
| Fri, 17 Nov 2023 | NT$48.3b | NT$2.1b | -NT$587,339,000.00 | 31.8x | -82.2x | 23.3x |
| Sun, 15 Oct 2023 | NT$47.7b | NT$2.2b | -NT$497,769,000.00 | 31.1x | -95.8x | 21.4x |
| Tue, 12 Sep 2023 | NT$43.1b | NT$2.2b | -NT$497,769,000.00 | 31x | -86.6x | 19.4x |
| Thu, 10 Aug 2023 | NT$45.9b | NT$2.5b | -NT$278,764,000.00 | 43.5x | -164.8x | 18.6x |
| Sat, 08 Jul 2023 | NT$48.8b | NT$2.5b | -NT$274,767,000.00 | 42.7x | -177.6x | 19.9x |
| Mon, 05 Jun 2023 | NT$50.0b | NT$2.5b | -NT$274,899,000.00 | 43.7x | -181.8x | 20.2x |
| Wed, 03 May 2023 | NT$46.8b | NT$2.7b | -NT$29,017,000.00 | 24.1x | -1612.6x | 17.6x |
Price to Earnings Ratio
-1612.6x
Current Industry PE
- Investors are pessimistic on the Taiwanese Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 17.1x is higher than the industry's current PS ratio of 14.1x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have deteriorated over the last three years.
- Revenues have also declined 2.0% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Comparison
How does Taiwanese Clinical Research and Equipment compare with similar industries?
| TW Market | 5.44% | |
| Healthcare | -3.12% | |
| Life Sciences | 1.78% | |
| Clinical Research and Equipment | 1.78% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6891 Locus Cell | NT$61.00 | 19.4% +NT$2.0b | 177.9% | PS958x | |
| 6986 HeXun Biosciences | NT$63.40 | 4.3% +NT$119.6m | -16.5% | PE26.1x | |
| 7837 Creative Life Science | NT$110.00 | 3.3% +NT$78.3m | n/a | n/a | |
| 6939 TFBS Bioscience | NT$21.10 | 4.2% +NT$29.7m | -15.9% | n/a |